Saturday 17 October 2026
Export GOSS’s income statement to Excel — free account
Gossamer Bio, Inc.
GOSS Healthcare Biotechnology
Gossamer Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $48.5 million, down 57.7% from fiscal 2024. In the quarter to June 2026, revenue fell 19.6%, EPS grew 129.4%, free cash flow grew 16.3% and total debt fell 81.7%, each against the same quarter a year earlier.
8.66
0.23
−2.59%
Follow GOSS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
P/S ratio |
14.62 | 0.00 | — | — | — | — | — | — | — | — |
Altman Z-Score |
(12.52) | (4.46) | — | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(30.36) | (8.77) | — | — | — | — | — | — | — | — |
Beneish M-Score |
0.74 | — | — | — | — | — | — | — | — | — |
P/Operating CF |
(14.66) | (5.77) | — | — | — | — | — | — | — | — |
P/B ratio |
0.00 | 6.94 | — | — | — | — | — | — | — | — |
Price to Tangible BV |
0.00 | 6.94 | — | — | — | — | — | — | — | — |
EV/Sales |
16.08 | 0.00 | — | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
EV/Operating CF |
(4.55) | (33.83) | — | — | — | — | — | — | — | — |
EV/FCF |
(4.55) | (30.26) | — | — | — | — | — | — | — | — |
Quick Ratio |
2.35 | 6.66 | 5.74 | 5.19 | 8.17 | 13.28 | 10.92 | 11.22 | 0.25 | 0.42 |
Current Ratio |
2.64 | 6.88 | 5.94 | 5.32 | 8.32 | 13.51 | 11.09 | 11.37 | 0.35 | 0.42 |
Net Debt/EBITDA |
(0.35) | 1.43 | 0.47 | 0.17 | 0.70 | 1.49 | 2.00 | 1.54 | (0.86) | 0.24 |
Debt/Assets |
115.24% | 62.65% | 67.01% | 80.50% | 52.97% | 32.63% | 7.22% | 0.00% | 1,357.30% | 0.00% |
Debt/Equity |
(1.62) | 6.70 | 3.33 | 18.16 | 1.50 | 0.55 | 0.09 | 0.00 | (0.88) | 0.00 |
Asset Turnover |
0.20 | 0.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.01 | 0.06 | 0.89 | 0.82 | 0.81 | 0.72 | 0.80 | 0.35 | 0.85 | (0.24) |
Capex/Depreciation |
0.01 | 0.00 | 0.00 | (0.10) | (0.13) | (0.18) | (3.08) | (11.75) | — | — |
Interest Coverage |
(15.54) | (5.20) | (13.60) | (15.75) | (11.12) | (18.47) | (96.05) | (12,416.08) | (56.38) | — |
| 365.33% | (122.54%) | (480.50%) | (343.53%) | (105.85%) | (72.30%) | (155.16%) | 231.57% | 193.87% | 2.38% | |
| (69.89%) | (18.03%) | (61.54%) | (74.46%) | (53.00%) | (50.38%) | (54.14%) | (122.54%) | (3,043.15%) | (37.30%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(163.39%) | (21.34%) | (70.09%) | (105.88%) | (78.73%) | (49.75%) | (47.72%) | (68.44%) | 824.73% | 100.00% |
Average Days of Receivables |
92.07 | 16.99 | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
359.17% | 120.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
77.64% | 31.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
21.78% | 17.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
(0.18) | 0.12 | — | — | — | — | — | — | — | — |
Graham Number |
240.87 | 0.00 | — | — | — | — | — | — | — | — |
Earnings Yield |
(24.19%) | (28.73%) | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(24.19%) | (1.89%) | — | — | — | — | — | — | — | — |
Revenue per Share |
16.97 | 40.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(59.96) | (1.23) | (83.42) | (176.91) | (201.91) | (205.93) | (211.65) | (627.85) | (50.17) | 0.00 |
Capex per Share |
(0.03) | 0.00 | 0.00 | (0.39) | (1.65) | (1.75) | (4.33) | (42.93) | 0.00 | 0.00 |
Free Cash Flow per Share |
(59.98) | (1.23) | (83.42) | (177.30) | (203.57) | (207.69) | (215.99) | (670.77) | (50.17) | 0.00 |
Cash per Share |
47.94 | 104.15 | 155.38 | 241.84 | 347.71 | 599.24 | 587.21 | 2,814.98 | 2.75 | 0.00 |
Shareholders Equity per Share |
(42.98) | 10.43 | 32.90 | 11.42 | 129.84 | 374.46 | 515.10 | (1,476.86) | (59.93) | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(42.98) | 10.43 | 32.90 | 11.42 | 129.84 | 374.46 | 515.10 | (1,476.86) | (59.93) | 0.00 |
Free Cash Flow |
(171.34) | (3.47) | (159.16) | (187.44) | (190.44) | (177.86) | (147.80) | (54.53) | (5.74) | 0.02 |
Working Capital |
104.21 | 264.88 | 254.92 | 212.65 | 291.92 | 483.67 | 372.39 | 211.55 | (0.82) | (0.08) |
Capital Expenditures |
(0.08) | — | — | (0.41) | (1.55) | (1.50) | (2.97) | (3.49) | — | — |
Net Current Asset Value |
(127.36) | 24.09 | 57.37 | 1.51 | 109.59 | 303.57 | 335.20 | (127.53) | (6.86) | 0.06 |
EV/EBIT |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(82.67) | (782.50) | (2.27) | 1.05 | 2.30 | 1.49 | 0.18 | 0.09 | — | — |
Cash ROIC |
(80.56%) | (0.66%) | (28.01%) | (38.48%) | (30.29%) | (17.61%) | (18.82%) | (50.13%) | 1,133.14% | 20.00% |
Accounts Receivable Turnover |
5.52 | 41.42 | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
8.78 | 2.77 | — | — | 0.20 | 0.85 | 0.85 | — | — | — |
Average Payables |
4.14 | 3.92 | 3.49 | 2.35 | 5.38 | 4.23 | 1.57 | 1.14 | 1.14 | — |
Average Assets |
243.77 | 313.60 | 292.18 | 308.05 | 441.55 | 483.02 | 333.01 | 119.93 | 0.22 | 0.22 |
Average Common Equity |
(46.63) | 46.13 | 37.42 | 66.77 | 221.07 | 336.58 | 116.21 | (63.47) | (3.49) | (3.49) |
Columns are period end dates